Cambridge Investment Research Advisors
LABP

Cambridge Investment Research Advisors’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Cambridge Investment Research Advisors’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,883
Closed -$275K – 3305
2021
Q3 		$275K Buy
+1,883
New +$244K ﹤0.01% 2538

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cambridge Investment Research Advisors's LABP Position: Q4 2021 in Review

Cambridge Investment Research Advisors sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q4 2021, closing a stake of 1,883 shares — an estimated $275K sold.

Cambridge Investment Research Advisors first reported a position in LABP in Q3 2021 and held it in 1 quarter. The position peaked at $275K in Q3 2021. 40 funds tracked by Wall St. Rank hold LABP as of Q4 2021.

  • Cambridge Investment Research Advisors reported no remaining Landos Biopharma, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,883 Landos Biopharma, Inc. Common Stock shares in Q4 2021, an estimated $275K.
  • Cambridge Investment Research Advisors first reported a position in Landos Biopharma, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Landos Biopharma, Inc. Common Stock position peaked at $275K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q4 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.